CCR9


Also found in: Acronyms.

CCR9

A gene on chromosome 3p21.3 that encodes a member of the beta chemokine receptor family, which is similar to G protein-coupled receptors. CCR9 is differentially expressed by T cells of the small intestine and colon, suggesting functional immune specialisation in the GI tract. Its ligand is CCL25.
Mentioned in ?
References in periodicals archive ?
Traficet-EN, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the activity of the CCR9 chemokine receptor.
ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease.
We assessed tumor cells in the small intestine for CCR9 and demonstrated it with high significance compared with metastasis to other organs," Hoon said.
These data will be included in a presentation entitled "Pharmacological Inhibition of Gut-Homing CCR9 T-cells Alters Disease Severity in Murine Models of Inflammatory Bowel Disease" as part of Session VI B: Original basic and clinical research abstract presentations on Saturday, December 2, 2006 at 3:40 p.
The Phase 2 data were presented today at the UEGW meeting in an oral presentation entitled "CCX282-B, an Orally Active Inhibitor of Chemokine Receptor CCR9, in a Randomized, Double-blind, Placebo-controlled Phase 2 Study in Moderate to Severe Crohn's Disease" (Abstract #OP-G-93) delivered by Satish Keshav, M.
Traficet-EN is intended to control the inappropriate inflammatory response underlying IBD by targeting the CCR9 chemokine receptor.
ChemoCentryx scientists presented these data in a poster entitled "A New Approach for Oral Therapy in IBD: Traficet-EN(TM), An Antagonist for CCR9 -- Efficacy in Preclinical Models and Early Clinical Data".
Traficet-EN is a novel, orally bioavailable, anti-inflammatory agent that targets the chemokine receptor known as CCR9.
ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.
ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.